# Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

> **NCT00902135** · — · COMPLETED · sponsor: **Bayer** · enrollment: 702 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)

## Key facts

- **NCT ID:** NCT00902135
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-08
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2015-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902135, "Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00902135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*